Organisation Strategy for
Denmark’s engagement with
International AIDS Vaccine Initiative (IAVI)
2014-2018
The work of IAVI
IAVI is a non-profit product development
partnership (PDP) with a mission to ensure
the development of an effective preventive
AIDS vaccine with a special focus on the
HIV virus strains prevalent in developing
countries.
PDPs are non-profit product development
partnerships which generate resources and
forge partnerships across public, private and
philanthropic
sectors
to
accelerate
development of new health technologies.
Denmark supports IAVI because
An AIDS vaccine is needed in order to
effectively end the AIDS pandemic.
Industry research into an AIDS vaccine
is limited due to perceived uncertain
return on investment compared to
research and development cost.
It is in line with Denmark’s strategic
ambition of being at the forefront of the
response to HIV and AIDS.
Key challenges for IAVI
Attracting sufficient funding as research
requires long-term funding and
outcomes are not certain.
An ever mutating HIV virus.
Denmark will expect IAVI to
Maintain a clinical pipeline of AIDS
vaccines relevant for parts of the world
with the highest burden of HIV, thereby
increasing the likelihood of a vaccine.
Strengthen research capacity in
developing countries including South-
driven research.
Denmark will follow-up by
Monitoring Danish priority areas based
on IAVI’s own framework.
Participating in annual donor
consultations and close dialogue.
IAVI
Established
1996
HQ
New York, NY, USA
Regional offices
Amsterdam, The
Netherlands; Nairobi,
Kenya; Johannesburg,
South Africa; and New
Delhi, India
Human
155
resources
CEO
Margaret G. McGlynn
Financial
resources
Denmark’s
contribution
66.6 mill. USD (2013)
5 mill. DKK annually
Donors (2014 projections)
BMGF: Bill & Melinda Gates Foundation
US NIH: National Institutes of Health